Brief Report: Three-Year Overall Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC - Update From PACIFIC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2019.10.002
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

PL02.01 Overall Survival With Durvalumab Versus Placebo After Chemoradiotherapy in Stage III NSCLC: Updated Results From PACIFIC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial

Clinical Cancer Research
Cancer ResearchOncology
2011English

Favorable Response to Pembrolizumab After Durvalumab Failure in a Stage III Sarcomatoid Carcinoma of the Lung: A Case Report

BMC pharmacology & toxicology
MedicinePharmacology
2020English

Durvalumab Extends OS in NSCLC

Cancer Discovery
Oncology
2018English

Osimertinib Plus Durvalumab Versus Osimertinib Monotherapy in EGFR T790m-Positive NSCLC Following Previous EGFR-TKI Therapy: CAURAL Brief Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Better Overall Survival With Advanced Radiation Treatment Modalities in Stage II and III Non-Small Cell Lung Cancer (NSCLC): A National Cancer Data Base Analysis

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2016English

Pre-Treatment CT Radiomics to Predict 3-Year Overall Survival Following Chemoradiotherapy of Esophageal Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2018English

PD-L1-Antikörper Durvalumab Verlängert Überleben Bei NSCLC Im Stadium III

Pneumologie
MedicinePulmonaryRespiratory Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy